Swissmedic resumes Inspections
Recommendation

2/3 September 2026
Copenhagen, Denmark
When “Human Error” isn’t enough: Successful Failure Investigation
Swissmedic, the Swiss Agency for Therapeutic Products, has announced "to resume regular on-site inspections", provided that the "necessary protective measures can be complied with". A safe inspection procedure must be guaranteed for all those involved.
Before the GMP/GDP inspection, the company to be inspected must fill out a questionnaire. This questionnaire contains instructions and measures which should be observed during the inspection. The companies are asked to complete the questionnaire and to confirm the measures accordingly.
On site, the inspected company must then make appropriate arrangements, such as "meeting rooms with sufficient space, restricted number of participants, electronic resources" and wearing face masks if necessary.
Related GMP News
22.07.2026Pre-approval Inspections: FDA introduces New Guidance
22.07.2026Do you know about QPSHARE?
08.07.2026How to (not) use AI for GxP Inspection Responses
01.07.2026Should TGA publish GMP Certificates?
24.06.2026Quality Unit (QU) in the Focus of a Warning Letter: Oversight Failures and FDA Expectations
03.06.2026GMP Auditor Association Developments January through April 2026


